Cellebrite Stock: Rating Downgrade As Valuation Has Caught Up (NASDAQ:CLBT)
Summary A brief update from my last coverage (11th July): I gave Cellebrite (NASDAQ:CLBT) a buy rating as the business’s strong competitive advantage, mission-critical